OPTN and amyotrophic lateral sclerosis: In addition, given that ALS-linked TBK1 deficiency may induce neurodegeneration by blocking downstream mitophagy signaling, our study not only highlights the FDA-approved drug gefitinib as a potential clinical treatment for TBK1-mediated ALS but also provides new insights into the downstream mitophagic regulator OPTN as a new target for pharmacology research in the future.